EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Extracellular matrix reprogramming by the YAP/TAZ/TGF-β2 axis drives immune exclusion in cholangiocarcinoma models

Marco Jessen, KyungMok Kim, Marie Tollot-Wegner, Anita Cindric Vranesic, Cagla Dönmez, Celina Junker, Tina Lehmann, Advitiya Khandelwal, Yuliya Kurlishchuk, Tom Hünniger, Christin Ritter, Evaristo Di Napoli und 12 weitere

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci201579 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Marco Jessen und 23 weiteren Autor:innen. Beteiligte Einrichtung: Transcriptional Control of Tissue Homeostasis Lab, Leibniz Institute on Aging, Fritz Lipmann Institute e.V. (FLI), Jena, Germany. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Extracellular Matrix, Adaptor Proteins, Signal Transducing, Transforming Growth Factor beta2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wilhelm Sander-Stiftung, Federal Ministry of Education and Research, German Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), key effectors of the Hippo pathway, are often hyperactivated in cancer, promoting tumor progression and therapy resistance. Their oncogenic role depends on interaction with TEA domain (TEAD) transcription factors, making the TEAD-YAP/TAZ complex a promising therapeutic target. Using translational mouse models, we show here that sustained systemic depletion of YAP and TAZ (YAP/TAZ) caused severe side effects. These could be avoided through pulsed inhibition, which effectively suppressed tumor growth, even at advanced stages. We identified Tgfb2 as a critical YAP/TAZ target gene for tumor formation and demonstrated that YAP/TAZ drove T cell exclusion via activation of tissue-remodeling genes. Consequently, YAP/TAZ inhibition enhanced immune cell infiltration. However, infiltrating T cells rapidly underwent exhaustion. Combining YAP/TAZ inhibition with immune checkpoint blockade reversed this exhaustion and sensitized resistant tumors to immunotherapy. This combination reshaped the tumor microenvironment to support immune cell infiltration and activation, representing a therapeutic strategy that maximizes antitumor immunity while minimizing toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaExtracellular MatrixAdaptor Proteins, Signal TransducingTransforming Growth Factor beta2Transcription FactorsBile Duct NeoplasmsSignal TransductionNeoplasm ProteinsNeoplasms, ExperimentalAnimalsMiceYAP-Signaling ProteinsHumansTumor MicroenvironmentTrans-ActivatorsCell Cycle ProteinsTranscriptional Coactivator with PDZ-Binding Motif ProteinsAcyltransferasesT-Lymphocytes

Stichwörter der Autor:innen

Cancer immunotherapyExtracellular matrixHepatologyLiver cancerOncology

Substanzen

YAP-Signaling ProteinsYap1 protein, mouseAdaptor Proteins, Signal TransducingTransforming Growth Factor beta2Transcription FactorsTrans-ActivatorsNeoplasm ProteinsCell Cycle ProteinsWwtr1 protein, mouseTranscriptional Coactivator with PDZ-Binding Motif Proteins

Autor:innen und Institutionen

  • Transcriptional Control of Tissue Homeostasis Lab, Leibniz Institute on Aging, Fritz Lipmann Institute e.V. (FLI), Jena, Germany.
  • Department of Veterinary Medicine and Animal Production, University of Naples Federico II, Naples, Italy.
  • Institute of Pathology, University of Würzburg, Würzburg, Germany.
  • Institute of Immunology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg - University Mainz, Mainz, Germany.
  • Vivace Therapeutics Inc., San Mateo, California, USA.
  • Department of Hematology and Oncology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.

Förderung

  • Wilhelm Sander-Stiftung
  • Federal Ministry of Education and Research
  • German Research Foundation
  • German Cancer Aid
  • Leibniz Collaborative Excellence
  • Federal Ministry of Research, Technology and Space

Zitieren

APA

Jessen, M., Kim, K., Tollot-Wegner, M., Cindric Vranesic, A., Dönmez, C., Junker, C., Lehmann, T., Khandelwal, A., Kurlishchuk, Y., Hünniger, T., Ritter, C., Di Napoli, E., Krishnan Murali, S., Bücking, K., Haug, V., Muth, S., Tang, T. T., Rosenwald, A., Radsak, M., …, & von Eyss, B. (2026). Extracellular matrix reprogramming by the YAP/TAZ/TGF-β2 axis drives immune exclusion in cholangiocarcinoma models. Journal of Clinical Investigation. https://doi.org/10.1172/jci201579

Vancouver

Jessen M, Kim K, Tollot-Wegner M, Cindric Vranesic A, Dönmez C, Junker C, et al. Extracellular matrix reprogramming by the YAP/TAZ/TGF-β2 axis drives immune exclusion in cholangiocarcinoma models. Journal of Clinical Investigation. 2026. doi:10.1172/jci201579

BibTeX
@article{Jessen2026,
  author = {Jessen, Marco and Kim, KyungMok and Tollot-Wegner, Marie and Cindric Vranesic, Anita and Dönmez, Cagla and Junker, Celina and Lehmann, Tina and Khandelwal, Advitiya and Kurlishchuk, Yuliya and Hünniger, Tom and Ritter, Christin and Di Napoli, Evaristo and Krishnan Murali, Shyam and Bücking, Konrad and Haug, Viktoria and Muth, Sabine and Tang, Tracy T and Rosenwald, Andreas and Radsak, Markus and Inverso, Donato and Deckert-Gaudig, Tanja and Deckert, Volker and Paciello, Orlando and von Eyss, Björn},
  title = {Extracellular matrix reprogramming by the YAP/TAZ/TGF-β2 axis drives immune exclusion in cholangiocarcinoma models},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci201579}
}
Kostenlos starten →